8-K
filed September 15, 2022, 7:59 PM ET
ticker LSTA
CIK 0000320017
M&A
confidence high
sentiment positive
materiality 0.85
Lisata Therapeutics formed via Caladrius-Cend merger; ~$76M cash, ticker LSTA
LISATA THERAPEUTICS, INC.
- Merger closed 9/15/22: Caladrius issued 0.5338 shares per Cend share after 1:15 reverse split; post-merger shares ~7.82M.
- Former Caladrius stockholders own ~52%, former Cend stockholders ~48% of combined company.
- Combined cash and investments ~$76M; focus on CendR Platform oncology pipeline and existing programs.
- Name changed to Lisata Therapeutics; ticker LSTA on Nasdaq; former ticker CLBS discontinued.
- Board expanded with four Cend designees; David Slack named President & CBO; leadership team includes CEO David Mazzo.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Anne C. Whitaker resigned as Director at LISATA THERAPEUTICS, INC..
- Action
- resigned
- Role
- Director
Exact text from the filing
Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael H. Davidson resigned as Director at LISATA THERAPEUTICS, INC..
- Action
- resigned
- Role
- Director
Exact text from the filing
Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Peter G. Traber resigned as Director at LISATA THERAPEUTICS, INC..
- Action
- resigned
- Role
- Director
Exact text from the filing
Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Steven S. Myers resigned as Director at LISATA THERAPEUTICS, INC..
- Action
- resigned
- Role
- Director
Exact text from the filing
Michael H. Davidson, M.D., Steven S. Myers, Peter G. Traber, M.D. and Anne C. Whitaker (the “Departing Directors”) resigned from the Company’s board of directors
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Slack was appointed as President and Chief Business Officer at LISATA THERAPEUTICS, INC..
- Action
- appointed
- Role
- President and Chief Business Officer
Exact text from the filing
appointed David Slack as a member of the Company’s board of directors and as the Company’s President and Chief Business Officer.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.